DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20162296

Non valvular atrial fibrillation stroke risk stratification by CHA2DS2-VASc score and short term outcomes

Madhuri Sunil Pandharipande, Shivraj V. Shinde, Mrinalini Dinkar Motlag, Keshav Nagpure, Rakhi W. Joshi, Prashant P. Joshi

Abstract


Background: Atrial fibrillation confers a high risk of stroke and is associated with significant mortality and morbidity. Many scoring systems for have been proposed stroke risk stratification in atrial fibrillation. Peripheral thromboembolism, heart failure and death. The main objective of the study was to estimate CHA2DS2VASc score in cases of non valvular atrial fibrillation, to asses short term outcome in AF (stroke, thromboembolism, heart failure and death and to find out association of CHA2DS2VASc score with outcomes.

Methods: 64 cases (29 M, 35 F) of non valvular AF were included in this prospective observational study.CHA2DS2VASc score was calculated and cases were categorized into low (score 0), intermediate (score 1 ) and high risk (score 2 ) for development of stroke. Cases were clinically evaluated and investigated for type, etiology, complications and comorbidities.

Results: CHA2DS2VASc score was determined in 64 cases of non valvular AF. In 3 cases (4.6%) it was zero indicating low risk for stroke, 8 cases (12.5%) had CHA2DS2VASc score as 1had intermediate risk, and 53 cases (82.8%) had score 2 or more indicating high stroke risk (p<0.01). 3 cases of non valvular atrial fibrillation (4.6%) presented with stroke and all of them had CHA2DS2VASc score>2. At the end of 3 months, total no. of cases with stroke was reported to be 5 (7.8 %). Stroke risk was significantly higher in cases of CHA2DS2VASc score>2 (p<0.01). Congestive heart failure was reported in 32 (50%) cases. Peripheral embolism was documented in 1 case (1.5%). Overall Mortality at the end of 3 months was reported to be 7 (10.9%) and cases with CHA2DS2VASc score ≥2 had 13% mortality. CHA2DS2VASc score ≥2 was significantly associated with mortality (p<0.01). All 3 Cases with CHA2DS2VASc score as zero were uncomplicated. 8 cases (12.5%) had score as 1 and, out of these 8 cases, CHF was reported in 2 cases (25%), while 6 (75%) were uncomplicated.CHA2DS2VASc score ≥2 was reported in 53 cases (82.3%). This group had complications in the form of CHF in 30 cases (56.6 %), thromboembolism in 1 (1.8%), and stroke in 5 (9.4%) cases. Cases of AF with CHA2DS2VASc score >2 demonstrated significantly high incidence for stroke as compared to those with score as zero or one (p<0.01).

Conclusions: CHA2DS2VASc is a simple score to predict stroke risk in cases of non valvular atrial fibrillation and is easy to estimate. CHA2DS2VASc score ≥2; is associated with high incidence of stroke in cases of non valvular AF. CHA2DS2VASc score≥2 is associated with mortality as a short term adverse outcome in non valvular atrial fibrillation.

 


Keywords


Atrial fibrillation, CHA2DS2-VASc score

Full Text:

PDF

References


Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted Country, Minnesota,1980 to 2000, and implications on the projections for the future prevalence. Circulation. 2004;110(9):1042-6.

Lip GY, Beevers DG. ABC of atrial fibrillation. History, epidemiology and importance of atrial fibrillation BMJ: British Medical Journal. 1995;311(7016):1361-3.

Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110:1042-6.

Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach : The Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263-72.

Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation of atrial fibrillation: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) European Heart Journal. 2010:31(19):2369-429.

Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. The influence of atrial fibrillation on prognosis in mild to moderate heart failure.The V-HeFT studies. The v- HeFTVa Cooperative Studies Group. Circulation. 1993;87(6-Suppl):VI102-10.

Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach : The Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263-72.

Stewart S, Hart CL, Hole DJ, McMurry Jj. A Population based study of long term risks associated eith atrial fibrillation;20 years follow up ofthe Renfrew/Paiseley study. The American Journal of Medicine. 2002;113(5):359-64.

Mant J, Hobbs FD, Fletcher K, Roafle A, Fitzmaurice D, Lip GYH, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Burmingham Atrial fibrillation Treatment of the Aged Study , BAFTA); a randomised controlled trial. Lancet. 2007;370(9586):493-503.

Wolf PA, Fauchier L, Lane DA. Risk factors for stroke and thromboembolism in relation to age among patientswith atrial fibrillation: the loire Valley Atrial fibrillation project. Chest. 2012;141(1):147-53.

Sandhu RK, Bakal JA, Ezekowitz JA, McAlister FA. Risk stratification schemes, anticoagulation use and outcomes: the risk treatment paradox in patients with newly diagnosed non valvular atrial fibrillation. Heart. 2011;97(24):2046-50.

Lévy S, Maarek M, Coumel P, Guize L, Lekieffre J, Medvedowsky JL et al. Characterisation of different subsets of atrial fibrillation in general practice in France: ALFA study. The College of French Cardiologists. Circulation. 1999;99(23):3028-35.

Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, et al. Atrial fibrillation management : a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. European heart journal. 2005;26(22):2422-34.

Farmakis D, Pipilis A, Antoniou A, Kaliambakos S, Goudevenos J, Anastasiou-Nana M, et al Clinical profile and therapeutic management of patients with atrial fibrillation in Greece: results from the Registry of Atrial Fibrillation to investigate new Guidelines (RAFTING).Hellenic journal of cardiology. HJC. 2013;54(5):368-75.

Kumar T, Soodan SS. Clinical and Echo-cardiographic Profile of atrial Fibrillation. JK science. 2011;13(2):73-6.

Levy S, Maarek M, Coumel P, Guize L, et al. Characterisation of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation. 1999;99(23):3028-35.

Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial. Lancet. 2007;370(9586):493-503.

Olesen GB, Fauchier L, Lane DA. Risk factors for stroke and and thromboembolism in relation to age among patients wirh atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest. 2012;141: 147-53.

Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182678 patients with atrial fibrillation : the Sweedish Atrial Fibrillation cohort study. European heart journal. 2012;33(12):1500-10.

Bharadwaj R. Atrial fibrillation in a tertiary care institute: A prospective study. Indian Heart J. 2012;64(5):476-8.